NEU 0.15% $13.13 neuren pharmaceuticals limited

Ann: Neuren completes Phelan-McDermid syndrome Phase 2 trial, page-50

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 929 Posts.
    lightbulb Created with Sketch. 354
    Re enrolment in other trials - maybe some savvy people are waiting for the PMS results - all 4 phase 1 trials are testing "the safety, tolerability, and efficacy of NNZ-2591".

    I know if I knew this and that there were results of a parallel trial due within weeks/days - I might just wait and enrol my child if/when the first phase 1 trial is positive or at least shows very little signs of unsafety, intolerability or non efficacy.

    And imho - it will be positive and that will just be a blockbuster event for Neuren and all of these people, opening many doors for the way ahead.
    Last edited by giarc63: 30/11/23
 
watchlist Created with Sketch. Add NEU (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.